Vaccines,
Год журнала:
2024,
Номер
12(6), С. 659 - 659
Опубликована: Июнь 14, 2024
The
escalating
global
healthcare
challenge
posed
by
Alzheimer’s
Disease
(AD)
and
compounded
the
lack
of
effective
treatments
emphasizes
urgent
need
for
innovative
approaches
to
combat
this
devastating
disease.
Currently,
passive
active
immunotherapies
remain
most
promising
strategy
AD.
FDA-approved
lecanemab
significantly
reduces
Aβ
aggregates
from
brains
early
AD
patients
administered
biweekly
with
humanized
monoclonal
antibody.
Although
clinical
benefits
noted
in
these
trials
have
been
modest,
researchers
emphasized
importance
preventive
immunotherapy.
Importantly,
data
immunotherapy
studies
shown
that
antibody
concentrations
periphery
vaccinated
people
should
be
sufficient
targeting
CNS.
To
generate
relatively
high
antibodies
at
risk
AD,
we
generated
a
universal
vaccine
platform,
MultiTEP,
and,
based
on
it,
developed
DNA
vaccine,
AV-1959D,
pathological
Aβ,
completed
IND
enabling
studies,
initiated
Phase
I
trial
volunteers.
Our
current
pilot
study
combined
our
advanced
MultiTEP
technology
novel
mRNA
approach
develop
an
encapsulated
lipid-based
nanoparticles
(LNPs),
AV-1959LR.
Here,
report
initial
findings
immunogenicity
1959LR
mice
non-human
primates,
comparing
it
its
counterpart,
AV-1959D.
Future Medicinal Chemistry,
Год журнала:
2025,
Номер
unknown, С. 1 - 17
Опубликована: Апрель 15, 2025
The
challenges
in
drug
discovery
aiming
to
mitigate
cancer
progression
are
the
thrust
area
of
scientific
research
for
several
decades.
Since
advent
heterocyclic
chemistry,
programs
have
made
significant
achievements
that
lead
development
numerous
drugs
with
broad
spectrum
potencies,
contributing
both
diagnostic
and
therapeutic
advancements.
Till
date,
efforts
discover
more
potent
efficient
candidates
underway
minimize
adverse
side
effects
existing
chemotherapeutics.
In
view
above,
small-molecule
agonists
can
interact
different
immune
modulators
like
toll
receptor-7
(TLR-7)
TLR-8
being
investigated
explored.
These
expected
display
profound
effect
on
anti-tumoral
activity
by
enhancing
production
proinflammatory
cytokines.
Recently,
imidazoquinoline
derivatives
proven
TLR
agonist
activities
emerged
as
promising
anticancer
therapeutics.
With
advancements
technology
evolution
new
scopes
discovery,
strategies
adopted,
particularly
help
nanotechnology,
immune-technology,
combination
etc.,
curb
various
types
cancers.
Herein,
novel
therapeutics
imidazoquinolines
reported
last
5
years,
their
structure-activity
relationship
along
important
synthetic
schemes
agonists,
discussed.
Vaccines,
Год журнала:
2025,
Номер
13(4), С. 424 - 424
Опубликована: Апрель 17, 2025
Vaccination
has
been
instrumental
in
curbing
the
transmission
of
SARS-CoV-2
and
mitigating
severity
clinical
manifestations
associated
with
COVID-19.
Numerous
COVID-19
vaccines
have
developed
to
this
effect,
including
BioNTech-Pfizer
Moderna’s
mRNA
vaccines,
as
well
adenovirus
vector-based
such
Oxford–AstraZeneca.
However,
emergence
new
variants
subvariants
SARS-CoV-2,
characterized
by
enhanced
transmissibility
immune
evasion,
poses
significant
challenges
efficacy
current
vaccination
strategies.
In
review,
we
aim
comprehensively
outline
landscape
emerging
concern
(VOCs)
sub-lineages
that
recently
surfaced
post-pandemic
years.
We
assess
effectiveness
existing
their
booster
doses,
against
these
subvariants,
BA.2-derived
sub-lineages,
XBB
BA.2.86
(Pirola).
Furthermore,
discuss
latest
advancements
vaccine
technology,
multivalent
pan-coronavirus
approaches,
along
development
several
next-generation
coronavirus
exosome-based,
virus-like
particle
(VLP),
mucosal,
nanomaterial-based
vaccines.
Finally,
highlight
key
critical
areas
for
future
research
address
evolving
threat
develop
strategies
combating
viral
threats,
thereby
improving
preparedness
pandemics.
Vaccines,
Год журнала:
2024,
Номер
12(6), С. 659 - 659
Опубликована: Июнь 14, 2024
The
escalating
global
healthcare
challenge
posed
by
Alzheimer’s
Disease
(AD)
and
compounded
the
lack
of
effective
treatments
emphasizes
urgent
need
for
innovative
approaches
to
combat
this
devastating
disease.
Currently,
passive
active
immunotherapies
remain
most
promising
strategy
AD.
FDA-approved
lecanemab
significantly
reduces
Aβ
aggregates
from
brains
early
AD
patients
administered
biweekly
with
humanized
monoclonal
antibody.
Although
clinical
benefits
noted
in
these
trials
have
been
modest,
researchers
emphasized
importance
preventive
immunotherapy.
Importantly,
data
immunotherapy
studies
shown
that
antibody
concentrations
periphery
vaccinated
people
should
be
sufficient
targeting
CNS.
To
generate
relatively
high
antibodies
at
risk
AD,
we
generated
a
universal
vaccine
platform,
MultiTEP,
and,
based
on
it,
developed
DNA
vaccine,
AV-1959D,
pathological
Aβ,
completed
IND
enabling
studies,
initiated
Phase
I
trial
volunteers.
Our
current
pilot
study
combined
our
advanced
MultiTEP
technology
novel
mRNA
approach
develop
an
encapsulated
lipid-based
nanoparticles
(LNPs),
AV-1959LR.
Here,
report
initial
findings
immunogenicity
1959LR
mice
non-human
primates,
comparing
it
its
counterpart,
AV-1959D.
